article thumbnail

Lilly agrees to acquire gene therapy developer Akouos for $610m

Pharmaceutical Technology

Eli Lilly and Company has signed a definitive agreement for the acquisition of all outstanding shares of precision genetic medicine firm Akouos for a total deal value of up to nearly $610m or up to $15.50 Akouos focuses on developing adeno-associated viral gene therapies to treat inner ear conditions, including sensorineural hearing loss.

article thumbnail

Intracellular Drug Delivery – Future Potential

Roots Analysis

Hence, a precision therapy or we can say a target therapy (involving intracellular drug delivery) is much needed to all the patients suffering from cancer. Here is how the intracellular drug delivery comes into action for majority of the fatal diseases that requires target therapy. The answer is yes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sano Genetics raises a further $11.4 million for its 'precision medicine revolution'

Outsourcing Pharma

Sano Genetics says it is developing software that will enable âthe precision medicine revolutionâ and has raised $11.4 million in new funding.

article thumbnail

Liposomes Development: Service Providers Landscape

Roots Analysis

In recent years, liposomes have garnered significant interest of researchers, as well as industry players, owing to their potential in diagnosis and treatment of various diseases, with a focus on delivering drugs and genetic material.

article thumbnail

Leading commercial dose (non-sterile) companies in contract marketing

Pharmaceutical Technology

The production of commercial dose non-sterile products such as tablets, capsules, ointments, creams, and powders is rising due to their growing global demand, attributed to increasing demand for anti-ageing products, hereditary factors, genetic mutations, exposure to harmful radiation, and rising geriatric population.

Marketing 130
article thumbnail

Evox Therapeutics acquires exosome AAV technology from Codiak

Drug Discovery World

“This is part of our long-term business strategy of leveraging exosome-mediated delivery to create and enable genetic medicines such as gene therapy and genome editors”.

article thumbnail

Lipid nanoparticles and mRNA used to treat hereditary blindness

Drug Discovery World

Oregon State University College of Pharmacy scientists have shown that lipid nanoparticles and messenger RNA could treat blindness associated with a rare genetic condition. . Researchers developed nanoparticles able to penetrate the neural retina and deliver mRNA to the photoreceptor cells whose proper function makes vision possible. .